异甘草酸镁注射液治疗肝硬化患者有效性和安全性的系统评价

目的 评价异甘草酸镁注射液治疗肝硬化的有效性和安全性。方法 应用计算机检索Pubmed、Embase、Cochrane library、中国生物医学文献数据库、数字化期刊数据库、中国学术期刊网络出版总库和中文科技期刊数据库。纳入异甘草酸镁注射液治疗肝硬化的随机对照试验，由两名评价者独立筛查文献、提取资料和进行偏倚风险评估，采用RevMan 5.2软件进行Meta分析。 结果 共纳入9篇随机对照试验，共567例肝硬化患者，本组纳入研究的方法学质量偏低；Meta分析结果显示，异甘草酸镁注射液单独或联合用药治疗的临床有效率优于其它保肝药物［RR 1.23，95%CI（1.07，1.42），P<0.01］和［RR 1.31，95%CI（1.13，1.51），P<0.01］，患者异常肝功能指标明显下降，且无严重不良反应发生。结论 异甘草酸镁注射液治疗肝硬化的有效性明显优于其它保肝药物，且不良反应发生率低，但尚需更多高质量研究进一步验证。

Efficacy and safety of magnesium isoglycyrrhizinate in the treatment of patients with cirrhosis:a systematic review

Objective To estimate the effectiveness and safety of magnesium isoglycyrrhizinate injection （MIG） for the treatment of patients with cirrhosis. Methods All the randomized controlled trials（RCT） about the effectiveness and safety of MIG for the treatment of patients with cirrhosis were collected by searching databases including Pubmed，Embse，Cochrane library，CBM，Wanfang，CNKI and VIP. The screening of literatures，extraction of information and evaluation of the risk of bias were accomplished by two independent reviewers. Statistical analyses were performed with RevMan 5.2 software. Results A total of 9 RCTs involving 576 patients were included，while the methodology of the included studies was of low quality. The meta-analysis showed that the clinical effective rate of MIG used alone or in combination with other liver-protecting agents was significantly higher than in other hepatoprotective drugs （RR: 1.23，95%CI: 1.07 to 1.42，P<0.01） and （RR:1.31，95%CI: 1.13 to 1.51，P<0.01） with remarkably improved liver function and no severe side effects. Conclusion MIG injection is superior to other hepatoprotective drugs for liver cirrhosis with fewer side effects. However，more controlled trials of high quality are required to further assess the effectiveness and safety of MIG for patients with cirrhosis.